Neoadjuvant combination immunotherapy in patients with advanced melanoma shows favorable activity over adjuvant treatment and warrants future evaluation with modified dosing schedules to reduce treatment-related adverse events.
- Christian U. Blank
- Elisa A. Rozeman
- Ton N. Schumacher